Supernus Pharmaceuticals Files 8-K with Exhibits

TL;DR

SUPERNUS files routine 8-K, no major news.

AI Summary

On April 8, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, indicating routine corporate activity rather than a specific material event. No new material agreements, executive changes, or significant financial transactions were detailed in the provided excerpt.

Why It Matters

This filing indicates Supernus Pharmaceuticals is adhering to its reporting obligations, which is standard practice for publicly traded companies. It does not appear to contain new material information that would immediately impact stock price.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report for financial statements and exhibits, suggesting no unusual or high-risk events.

Key Players & Entities

• Supernus Pharmaceuticals, Inc. (company) — Registrant
• April 8, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto

Filing Documents

• supn-20240408.htm (8-K) — 28KB
• ex99104-08x2024.htm (EX-99.1) — 11KB
• image_0.jpg (GRAPHIC) — 5KB
• 0001356576-24-000018.txt ( ) — 172KB
• supn-20240408.xsd (EX-101.SCH) — 2KB
• supn-20240408_lab.xml (EX-101.LAB) — 21KB
• supn-20240408_pre.xml (EX-101.PRE) — 12KB
• supn-20240408_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On April 8, 2024, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") issued a press release announcing that it had received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for SPN-830 (apomorphine infusion device) for the continuous treatment of motor fluctuations ("off" episodes) in Parkinson's disease. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. This Current Report on Form 8-K contains "forward-looking statements" that do not convey historical information, but relate to predicted or potential future events, such as statements of our plans, strategies and intentions. These statements can often be identified by the use of forward-looking terminology such as "believe," "expect," "intend," "may," "will," "should," or "anticipate" or similar terminology. All statements other than statements of historical facts included in this Current Report on Form 8-K are forward-looking statements. All forward-looking statements speak only as of the date of this Current Report on Form 8-K. Except for Supernus' ongoing obligations to disclose material information under the federal securities laws, Supernus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In addition to the risks and uncertainties of ordinary business operations and conditions in the general economy and the markets in which Supernus competes, the forward-looking statements of Supernus contained in this Current Report on Form 8-K are also subject to various risks and uncertainties, including those set forth in Item 1A, "Risk Factors," in Supernus' Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 — Press Release Dated April 8, 2024 furnished as an Exhibit pursuant to Item 8.01 hereof. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: April 8, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3